Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Polasek

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Frontiers in Digital Health|October 2, 2023
Virtual twin for healthcare managementThomas M Polasek
Frontiers in Genetics|May 22, 2023
Calculation of the pharmacogenomics benefit score for patients with medication-related problemsThomas M Polasek
Expert Review of Clinical Pharmacology|February 2, 2024
Pharmacogenomics - a minor rather than major force in clinical medicineThomas M Polasek
Clinical Pharmacology in Drug Development|June 23, 2023
Improving the Efficiency of Clinical Pharmacology StudiesThomas M Polasek, Virna Schuck
The Clinical Biochemist. Reviews|May 26, 2011
Drug dosing in renal diseaseMatthew P Doogue, Thomas M Polasek
Clinical Pharmacology and Therapeutics|February 15, 2020
Virtual Twins: Understanding the Data Required for Model-Informed Precision DosingThomas M Polasek, Amin Rostami-Hodjegan
Australian Prescriber|June 26, 2025
Using pharmacogenomics to personalise drug therapy: which drugs, when and howSophie L Stocker, Thomas M Polasek
Clinical Pharmacology and Therapeutics|December 22, 2025
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data"John O Miners, Thomas M Polasek
Therapeutic Advances in Drug Safety|March 30, 2018
Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patientsHeather L Forbes, Thomas M Polasek
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2007
In vitro approaches to investigate mechanism-based inactivation of CYP enzymesThomas M Polasek, John O Miners
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Frontiers in Digital Health|October 2, 2023
Virtual twin for healthcare managementThomas M Polasek
Frontiers in Genetics|May 22, 2023
Calculation of the pharmacogenomics benefit score for patients with medication-related problemsThomas M Polasek
Expert Review of Clinical Pharmacology|February 2, 2024
Pharmacogenomics - a minor rather than major force in clinical medicineThomas M Polasek
Clinical Pharmacology in Drug Development|June 23, 2023
Improving the Efficiency of Clinical Pharmacology StudiesThomas M Polasek, Virna Schuck
The Clinical Biochemist. Reviews|May 26, 2011
Drug dosing in renal diseaseMatthew P Doogue, Thomas M Polasek
Clinical Pharmacology and Therapeutics|February 15, 2020
Virtual Twins: Understanding the Data Required for Model-Informed Precision DosingThomas M Polasek, Amin Rostami-Hodjegan
Australian Prescriber|June 26, 2025
Using pharmacogenomics to personalise drug therapy: which drugs, when and howSophie L Stocker, Thomas M Polasek
Clinical Pharmacology and Therapeutics|December 22, 2025
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data"John O Miners, Thomas M Polasek
Therapeutic Advances in Drug Safety|March 30, 2018
Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patientsHeather L Forbes, Thomas M Polasek
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2007
In vitro approaches to investigate mechanism-based inactivation of CYP enzymesThomas M Polasek, John O Miners
Pageof 8